Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Multi Center Validation of a New Molecular Diagnostic Assay for Accurate and Rapid Screening of JAK2 V617F Mutation

Fabienne Hermitte, CSO, Ipsogen, speaking at the Molecular Diagnostics World Congress 2007
Date Posted: Monday, May 19, 2008

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

IPSOGEN Expands its U.S. Presence through Licensing Agreement with Quest Diagnostics
Ipsogen entered a non-exclusive license agreement with Quest for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Tuesday, October 07, 2008
IPSOGEN Expands its U.S. Presence Through Licensing Agreement with Quest Diagnostics
Ipsogen SA, a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemia, today announced a non-exclusive license agreement with Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, for the use of the JAK2 V617F mutation in Quest Diagnostic's laboratory developed tests.
Monday, October 06, 2008
Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results
The Company expects that by improving the accuracy of tumor grading, the test could spare tens of thousands chemotherapy treatments per year.
Monday, June 02, 2008
Ipsogen Announces Three Studies at the American Society of Clinical Oncology Meeting
The results from the studies extend the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer.
Monday, May 26, 2008
IPSOGEN Licenses the Genomic Grade™ to Improve Breast Cancer Diagnosis & Treatment Decision
IPSOGEN signed a license agreement with Universite Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™.
Monday, January 28, 2008
Ipsogen Reports Recommendation of JAK2V617F Mutation Screening in WHO 2008 Criteria and Point-of-Care Diagnostic Algorithms
The 2008 revision of the WHO document on the classification of CMPDs has incorporated new information on the molecular pathogenesis of BCR–ABL negative myeloproliferative disorders including the screening for JAK2V617F mutation.
Tuesday, January 22, 2008
IPSOGEN Grants Labcorp License for Leukemia Molecular Diagnostic Assay in USA
IPSOGEN grants LabCorp non-exclusive rights to offer an assay for the diagnosis of a group of leukemias caused by JAK2 gene variations.
Tuesday, September 11, 2007
Ipsogen Grants Exclusive License to Warnex to Market a Leukemia Molecular Diagnostic Service in Canada
Ipsogen grants Warnex exclusive rights to market a service for the diagnosis and the classification of a group of leukemias.
Thursday, August 16, 2007
Ipsogen Presents Breast Cancer Biomarker Results at the EBCC 5
These results concern the identification on 323 patient samples.
Monday, February 27, 2006
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
RNA Suppresses Inflammation
Researchers identify a long noncoding RNA that regulates innate immunity.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!